ImmunityBio Inc Ordinary Shares IBRX 深 滬
等待開盤 01-03 09:30:00 美东时间
2.025
+0.045
+2.27%
華盛通- 最 高2.07
- 今 開2.02
- 成交量 568.21万股
- 最 低 1.98
- 昨 收 1.98
- 總市值 19.95亿
- 52周最高 4.27
- 市盈率 靜 --
- 換手率 0.58%
- 52周最低 1.83
- 委 比 -28.73%
- 總股本 9.85亿
- 歷史最高 45.42
- 量 比 1.00
- 振 幅 4.55%
- 歷史最低 0.93
- 每 手 1
- 風險率 0.37%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多CDC signs off on change in newborn hepatitis b vaccine schedule
The CDC on Tuesday evening formally adopted a change in the newborn vaccine schedule that doesn't recommend all babies born to mothers who test negative for hepatitis b get the shot against the virus....
2025-12-17 12:03
美股大行评级 | 潜在涨幅263.64%！Milestone Pharmaceuticals获富国银行升目标价至8美元，维持"超配"评级
今日重点评级关注：富国银行：维持Milestone Pharmaceuticals"超配"评级，目标价从4美元升至8美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从31美元升至33美元
2025-12-17 10:46
ImmunityBio Appoints Bruce Wendel to Board
An update from ImmunityBio ( ($IBRX) ) is now available. On December 10, 2025, ...
2025-12-16 06:50
美股大行评级 | 博通、Lululemon获10逾家大行上调目标价；好市多、RH遭大行下调目标价
今日重点评级关注：杰富瑞：维持ImmunityBio Inc Ordinary Shares"买入"评级，目标价从8美元升至9美元；B. Riley证券：维持WAVE Life Sciences"买入"评级，目标价从19美元升至37美元
2025-12-15 15:30
Jefferies Maintains Buy on ImmunityBio, Raises Price Target to $9
Jefferies analyst Kelly Shi maintains ImmunityBio (NASDAQ:IBRX) with a Buy and raises the price target from $8 to $9.
2025-12-13 02:59
ImmunityBio Gains EMA Nod for ANKTIVA® in Europe
ImmunityBio ( ($IBRX) ) has issued an announcement. On December 12, 2025, Immun...
2025-12-12 20:28
ImmunityBio's Cancer Therapy Clears Major EU Hurdle, Opening Door To Earlier Access For Thousands Of Patients
ImmunityBio ((IBRX), a leading immunotherapy company, announced today that the European Medicines Agency has recommended granting a conditional marketing authorization in the EU for ANKTIVA® (nogapendekin alfa
2025-12-12 19:11
Micron, Endeavour Silver, First Majestic Silver, Applied Digital And Other Big Stocks Moving Higher On Friday
U.S. stocks were higher, with the Dow Jones gaining around 300 points on Friday...
2025-11-29 00:19
HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial Results
HCW Biologics reported its third-quarter 2025 financial results and business highlights, including the planned Phase 1 clinical trial for HCW9302, a novel immunotherapy targeting autoimmune diseases, and the launch of a search for a commercial partner for its T-cell engager compounds. The company also highlighted the IND-enabling studies for HCW9302 and showcased data for its second-generation TCE and immune checkpoint inhibitor programs. Despite...
2025-11-14 21:44
美股大行评级 | 思科、On Holding、派拓网络等获多家机构上调目标价；Circle 遭富国、德银等多家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持PDS Biotechnology"买入"评级，目标价从13美元升至15美元；HC Wainwright & Co.：维持PepGen Inc."买入"评级，目标价从18美元升至20美元
2025-11-14 10:43
